Femasys Q2 net loss narrows 2.55% to $4.47 million; net sales drop 18.9% to $331,827

• Femasys posted a Q2 net loss of USD 4.47 million, or USD 1.33 per share, versus a year-earlier net loss of USD 4.59 million.
• Net sales fell 18.9% to USD 331,827, on lower FemVue sales.
• Research and development expenses climbed 37.6% to USD 1.95 million, reflecting inventory transition to support commercialization and higher clinical costs.
• Completed a USD 30 million private placement, with potential proceeds up to USD 90 million upon full cash exercise of warrants.
• Management said the financing supports U.S. commercialization of FemaSeed Complete and advancement of the U.S. FemBloc clinical program toward approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141605PRIMZONEFULLFEED9810548) on August 14, 2026, and is solely responsible for the information contained therein.